HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $23
HC Wainwright & Co. analyst Douglas Tsao maintains Radius Health (NASDAQ:RDUS) with a Neutral and lowers the price target from $26 to $23.
Radius Health Q3 EPS $(0.32) Misses $(0.24) Estimate, Sales $56.81M Miss $61.27M Estimate
Radius Health (NASDAQ:RDUS) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.24) by 33.33 percent. This is a 313.33 percent decrease over earnings of $0.15 per share from
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Earnings Outlook For Radius Health
Radius Health (NASDAQ:RDUS) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Radius Health will likely report an Earnings Per Share (EPS) of $-0.24
HC Wainwright & Co. Maintains Neutral on Radius Health, Raises Price Target to $26
HC Wainwright & Co. analyst Douglas Tsao maintains Radius Health (NASDAQ:RDUS) with a Neutral and raises the price target from $19 to $26.
48 Biggest Movers From Yesterday
Gainers
Xiaobai Maimai Inc. (NASDAQ: HX) shares surged 98.4% to settle at $18.87 on Wednesday on above-average volume. The company on Tuesday disclosed the resignation of its CEO and Chairman and announced the appointment of Yilin Wang as CEO.
Mid-Day Market Update: Healthcare Services Drops After Q3 Results; Radius Health Shares Jump
Midway through trading Wednesday, the Dow traded up 0.40% to 35,598.89 while the NASDAQ rose 0.15% to 15,151.71. The S&P also rose, gaining 0.37% to 4,536.47.
Mid-Morning Market Update: Markets Open Higher; Verizon Posts Upbeat Earnings
Following the market opening Wednesday, the Dow traded up 0.35% to 35,580.21 while the NASDAQ rose 0.11% to 15,146.02. The S&P also rose, gaining 0.32% to 4,533.97.
Radius Health, Menarini Group Report Phase 3 Topline Results From EMERALD Trial For Elacestrant In Breast Cancer: ‘Study met both primary endpoints in patients with ER+/HER2- advanced or mBC’
Study met both primary endpoints in patients with ER+/HER2- advanced or mBC
Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of